FORTIS HEALTHCARE
|
|
BOM : 532843     NSE : FORTIS     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Aug 30,2024 |
Price(EOD): ₹ 551.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Hospital & Healthcare Services |
MCap: ₹ 41,653.35 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
FORTIS HEALTHCARE | 2% | 10% | 61.6% |
APOLLO HOSPITALS ENTERPRISE | 2.2% | 4.6% | 41.1% |
MAX HEALTHCARE INSTITUTE | 0.4% | -6.3% | 56.4% |
GLOBAL HEALTH | 7.1% | -8.6% | 59.6% |
NARAYANA HRUDAYALAYA | -0.8% | 1% | 22% |
ASTER DM HEALTHCARE | 0.4% | 17.2% | 25.4% |
FUNDAMENTAL ANALYSIS OF FORTIS HEALTHCARE
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF FORTIS HEALTHCARE
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
60.85
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 684.53 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 5.44
P/B Calculated based on Book Value of Rs 7,661.15 Cr
[Latest Year - Mar2024 - Consolidated Results ] 5.87
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 7,094.41 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
65% 139% 176% |
SHARE PRICE MOMENTUM OF FORTIS HEALTHCARE
FORTIS HEALTHCARE vs SENSEX
DEBT OF FORTIS HEALTHCARE
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.03 0.04 0.07 0.05 |
0.11 0.1 0.16 0.12 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF FORTIS HEALTHCARE
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF FORTIS HEALTHCARE
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
4.09% -10.11% -14.08% -12.79% |
12.16% 25.71% 33.91% 39.19% |
QtrlyTrend |
2 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
FORTIS HEALTHCARE related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 2.5% | 7.5% | 54.8% |
S&P BSE SMALLCAP SELECT INDEX | 1.4% | 1% | 47.7% |
S&P BSE 250 LARGEMIDCAP | 1.3% | 1.1% | 38.2% |
S&P BSE 500 | 1.3% | 1.2% | 39.5% |
S&P BSE ALLCAP | 1.2% | 1.2% | 40.7% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 200 | 1.4% | 1.4% | 38.5% |
NIFTY LARGE MIDCAP 250 | 1.4% | 1.1% | 43.3% |
NIFTY 500 | 1.4% | 1.3% | 40.2% |
NIFTY MIDCAP150 | 1.3% | 0.8% | 50.7% |
NIFTY500 MULTICAP 50:25:25 | 1.3% | 1.2% | 44.8% |
You may also like the below Video Courses
FAQ about FORTIS HEALTHCARE
Is FORTIS HEALTHCARE good for long term investment?
As on Aug 30,2024, the Fundamentals of FORTIS HEALTHCARE look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of FORTIS HEALTHCARE . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is FORTIS HEALTHCARE UnderValued or OverValued?
As on Aug 30,2024, FORTIS HEALTHCARE is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of FORTIS HEALTHCARE ?
As on Aug 30,2024, the Intrinsic Value of FORTIS HEALTHCARE is Rs. 230.43 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 334.17
Fair Value [Median EV / Sales Model] : Rs. 230.43
Fair Value [Median Price / Sales Model] : Rs. 200.06
Estimated Median Fair Value of FORTIS HEALTHCARE : Rs. 230.43
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.